CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 25 enrolled
Drug / intervention
Degludec +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04692415
NCT04692415Phase 4Completed
CompareCT.gov

The Differences Between Insulin Glargine U300 and Insulin Degludec U100 in Impact on the Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles in Insulin naïve Patients Suffering From Type Two Diabetes Mellitus

University of Split, School of Medicine·interventional·Posted Dec 31, 2020·Updated Dec 31, 2020

In Brief

A Phase 4 clinical trial evaluating Degludec and Glargine U300 for Diabetes Mellitus, Type 2. Completed, enrolled 25 participants across 1 site.

Detailed Summary

To compare the impact of insulin degludec (IDeg-100) and insulin glargine U300 (IGlar-300) on cardiovascular risk parameters - glycaemic variability (GV), oxidative stress, arterial stiffness and lipid parameters - in insulin naive patients with DMT2.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesCroatia
CollaboratorsPavle Vrebalov Cindro, Jonatan Vuković, Darko Modun, Božo Smajić, Gordan Kardum, Tina Tičinović Kurir, Doris Rušić, Ana Šešelja Perišin, Josipa Bukić

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedDec 31, 2020
Enrollment StartDec 15, 2018
Primary CompletionJun 27, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.5 years ago

Interventions

Degludecdrug

treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles

Glargine U300drug

treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles